header logo image


Page 34«..1020..33343536..4050..»

Archive for the ‘Arthritis’ Category

Treatment gets five out of Intensive Care – Dominican Today

Sunday, March 29th, 2020

At least five patients, including some doctors, have overcome the critical state of health in which they had fallen due to the coronavirus and been moved from the Intensive Care units to normal hospital wards, after undergoing an expensive treatment that is producing good results.

Of the patients who have responded adequately to treatment, there are four from Santiago: Dr. Daniel Rivera, president of the Board of Directors of the Unin Mdica Clinic, urologist Fausto Hernndez, ex-governor Jos Izquierdo and patient Juan Ramn. In Santo Domingo, the political leader of San Pedro de Macors, Senator Jos Hazim, while Dr. Felix Antonio Cruz Jiminin has presented significant improvement, although he is still in intensive care with mechanical respiration, admitted to the General Hospital of the Plaza de health.

The details were offered by the Minister of Public Health, Rafael Snchez Crdenas, on the eighth day of the virtual press conference to report the updates to the Covid-19.He said it is a non-over-the-counter medicine that is applied intravenously and is applied to critically ill patients with complicated pneumonia.

A drug used in the treatment of arthritis patients has been applied to these patients.It is tocilizumab, a biological medicine, which is supplied through the High-Cost Medicines Program of the Ministry of Public Health.

Tocilizumab (Actemra) is a biologic medication approved to treat rheumatoid arthritis (RA) in adults, polyarticular juvenile rheumatoid arthritis (JRA), and the systemic form of juvenile idiopathic arthritis (JIA) in children. It isused to suppress the immune system in autoimmune diseases.

Biological drugs are artificial and manufactured using genetic engineering techniques and are closely related to a protein that the body produces naturally.

Dr. Snchez Crdenas reported that there are nine doctors registered with the virus, of whom four were in the process of their work, and others were infected on a cruise or airplane trip, and about three nurses.

He recalled that the highest risk of death is in people over 60 years old and people with co-morbidities, so he called people to take more extreme care of older adults.

Cross-testsThe Minister of Public Health, Rafael Snchez Crdenas, announced that from yesterday the trial would begin with cross-tests at the Dr. Defill National Laboratory, in order to speed up the confirmation of Covid-19 cases.

THE PROCESSSnchez Crdenas revealed that starting today, Saturday, rapid tests of up to 15 minutes will be made, through blood collection obtained from the pulpejo, with patients who have tested positive for other types of tests, to confirm their effectiveness, and then put them into service.

The testsThe effectiveness of rapid tests can be as high as 95%, and the PCR tests, which are being applied in the laboratory, are a specific test with 95% effectiveness, said Crdenas.Those 15-minute rapid tests, of which there are already samples in the country, will be tested today with patients.

Continued here:
Treatment gets five out of Intensive Care - Dominican Today

Read More...

Evaluating the Treatment of Acute Gout Flares in the Emergency Department – Rheumatology Advisor

Sunday, March 29th, 2020

With the rise in number of opioid addictions, alternative long-term care and acute flare management for gout should be further addressed, according to a letter to the editor published in Arthritis Care & Research.1

Researchers previously reported on the diagnosis and treatment of acute gout flares in a 541 consecutive emergency department (ED) visits over a 7-year period.2 They indicated that among patients who visited the ED for an acute gout flare, 35% received an opioid (oxycodone/acetaminophen) and 52% received a prescription for an opioid. According to another study, opioids were prescribed more than 50% of the time in the ED for acute gout flares3; however, the researchers pointed out that the use of analgesia alone does not treat gouty inflammation.

Researchers of this study noted that treatment programs need to consider that gout is a long-term, chronic disease that requires continuous management; the possibility that acute flare-ups can occur must be considered. Research is necessary to address if the use of opioids for acute gout flares in the ED is warranted as well as to establish evidence-based guidelines for treating gout flares.

[T]he clinical importance of this study is that it will increase discussion about the treatment of acute gout flares in the ED and beyond, the investigators concluded.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

References

1. Schlesinger N, Brunetti L. Treatment of acute gout flares in the emergency department [published online February 14, 2020]. Arthritis Care Res (Hoboken). doi:10.1002/acr.24166

2. Oster A, Bindman AB. Emergency department visits for ambulatory care sensitive conditions: insights into preventable hospitalizations. Med Care. 2003;41:198-207.

3. Dalal DS, Mbuyi N, Shah I, Reinert S, Hilliard R, Reginato A. Prescription opioid use among acute gout patients discharged from the emergency department [published July 2, 2019]. Arthritis Care Res. doi:10.1002/acr.23928

Follow this link:
Evaluating the Treatment of Acute Gout Flares in the Emergency Department - Rheumatology Advisor

Read More...

BREAKING: Tolicizumab (Actemra) shown to be more effective than hydroxychloroquine in treating coronavirus patients, Italian doctors say -…

Sunday, March 29th, 2020

For the past two weeks now, weve been talking about hydroxychloroquine as the wonder drug in the fight against the deadly coronavirus. Two anti-malaria drugs hydroxychloroquine and chloroquine are shown to be effective in treating COVID-19 patients after controlled clinical study conducted by doctors in France shows that a combo of Hydroxychloroquine and Azithromycin (Z-Pak) cures 100% of coronavirus patients within 6 days of treatment.

However, according to doctors treating coronovirus patients in Italy, Tolicizumab, a drug used to treat moderate to severe rheumatoid arthritis, has been shown to be more effective than hydroxychloroquine.Tolicizumab is so effective that the FDA gives green lights to Phase III Tocilizumab Trial for COVID-19 pneumonia. In a related report, Italian doctors said that a 101-year-old Italian man who survived the 1918 Spanish flu pandemic and World War II, recovered from COVID-19.

In another report, scientists claim Tocilizumab has been shown to help cure 95 percent of critically ill coronavirus patients in China. Tocilizumab, which is marketed as Actemra, is taken by patients with rheumatoid arthritis toreduce inflammation.Chinese doctors gave it to 20 patients during the peak of of coronavirus epidemic.Nineteen of the patients were discharged within 14 days despite being critically ill.Actemra has now been approved for use in China and for trials in the US

In response to a question from another doctor on hydroxychloroquine, Dr. Giusppe Galati, an Italian doctor, said in a tweet: Dear@DrLuizSilva1despite the large noise on social media. Here in Flag of Italy they are trying several combinations of antiviral included the combination HCQ + azithro. Infectivologist refer little benefit. The unique drug which is causing impressive improvement is#Tolicizumab.

Tocilizumab, also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R).

Dear Giuseppe @GiuseppeGalati_ Are the patientes being treated with HCQ an Azithronycin in Italy ? What are the results? Do you start these medicarions as soon as the symptoms begin or late in the courso of disease ?

Dr. Luiz Silva (@DrLuizSilva1) March 20, 2020

The FDA approved the double-blind, randomized phase III clinical trial of the oncology supportive care drug tocilizumab (Actemra) for use in combination with standard of care for the treatment of hospitalized adult patients with severe COVID-19 pneumonia, according to Genentech (Roche), the manufacturer of the interleukin-6 receptor antagonist.

Genentech is also working with the Biomedical Advanced Research and Development Authority (BARDA), a part of the US Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR), to evaluate tocilizumab combined with standard of care versus placebo plus standard of care. In a press release,Genentech said it is providing 10,000 vials of tocilizumab to the United States Strategic national stockpile for potential future use as determined by the US Department of Health and Human Services.

We thank the FDA for rapidly expediting the approval of this clinical trial to evaluate Actemra in critically ill patients suffering from pneumonia following coronavirus infection and were moving forward to enroll as quickly as possible, Alexander Hardy, chief executive officer of Genentech, said in the press release.

Conducting this clinical trial in partnership with BARDA and providing Actemra to support the national stockpile, through the efforts of Secretary Azar and HHS, are important examples of how the US government the biotechnology industry and healthcare communities are working together in response to this public health crisis, added Hardy.

See the original post:
BREAKING: Tolicizumab (Actemra) shown to be more effective than hydroxychloroquine in treating coronavirus patients, Italian doctors say -...

Read More...

Arthritis Foundation | Symptoms Treatments | Prevention Tips …

Saturday, March 21st, 2020

As a partner, you will help the Arthritis Foundation provide life-changing resources, science, advocacy and community connections for people with arthritis, the nations leading cause of disability. Join us today and help lead the way as a Champion of Yes.

Our Trailblazers are committed partners ready to lead the way, take action and fight for everyday victories. They contribute $2,000,000 to $2,749,000

Our Visionary partners help us plan for a future that includes a cure for arthritis. These inspired and inventive champions have contributed $1,500,00 to $1,999,999.

Our Pioneers are always ready to explore and find new weapons in the fight against arthritis. They contribute $1,000,000 to $1,499,999.

Our Pacesetters ensure that we can chart the course for a cure for those who live with arthritis. They contribute $500,000 to $999,000.

Our Signature partners make their mark by helping us identify new and meaningful resources for people with arthritis. They contribute $250,000 to $499,999.

Our Supporting partners are active champions who provide encouragement and assistance to the arthritis community. They contribute $100,000 to $249,999.

Read more:
Arthritis Foundation | Symptoms Treatments | Prevention Tips ...

Read More...

Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Period – Yahoo…

Saturday, March 21st, 2020

- Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030

- Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

LONDON, March 18, 2020 /PRNewswire/ -- The global Rheumatoid Arthritis market is estimated to have reached $58bn in 2018 and is expected to grow at a CAGR of 0.6% in the second half of the forecast period. In 2018, the biologics submarket held 85% of the global Rheumatoid Arthritis market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new236-page reportyou will receive180 tables and 121 figures all unavailable elsewhere.

The 236-page Visiongain report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/#download_sampe_div

Report Scope

Global Rheumatoid Arthritis Marketforecast from 2020-2030

Revenue forecasts for theRheumatoid Arthritis Market by Drug Classfrom 2020-2030: Biologics Non-Biologics: NSAIDs, sDMARDs, Others

Revenue forecasts for theRheumatoid Arthritis Market by Drugsfrom 2020-2030: Humira Enbrel Remicade Rituxan/MabThera Simponi/Simponi Aria Orencia Actemra/Roactemra Cimzia Celebrex Xeljanz Arcoxia Others

Revenue forecasts for theRheumatoid Arthritis Market by Regionfrom 2020-2029: North America: U.S., Canada Europe: Germany, UK, France, Italy, Spain, Russia, Rest of Europe Asia-Pacific: Japan, China, India, Rest of Asia-Pacific Latin America: Brazil, Mexico, Rest of Latin America Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA

Profiles of these selected leading companies: AbbVie Amgen, Inc. Bristol-Myers Squibb Eli Lilly and Company F. Hoffmann-La Roche Ltd Johnson & Johnson Merck & Co. Novartis AG Pfizer Sanofi S.A. UCB

Analysis of the Drivers, Restraints, Opportunities and Threats of the global rheumatoid arthritis drugs market

The report also includes SWOT Analysis of the Global rheumatoid arthritis drugs market

Key questions answered by this report: How is the Rheumatoid Arthritis drugs market evolving? What is driving and restraining the Rheumatoid Arthritis drugs market? What are the market shares of each segment of the overall Rheumatoid Arthritis drugs market in 2018? How will each Rheumatoid Arthritis drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030? How will the market shares for each Rheumatoid Arthritis drugs submarket develop from 2020 to 2030? Which individual therapies will prevail and how will these shifts be responded to? What will be the main driver for the overall market from 2020 to 2030? How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030? Who are the leading players and what are their prospects over the forecast period? How will the industry evolve during the period between 2020 and 2030?

Story continues

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

4SCAbbVieAbivaxAblynx NV SanofiAdheron Therapeutics, Inc.Akari Therapeutics PlcAlder BiopharmaceuticalsAmgenAnacorAraim Pharmaceuticals, Inc.argenxArtax Biopharma, Inc.Astellas Pharma IncBaxalta IncorporatedBiocon Ltd.BiogenBioxpress TherapeuticsBoehringer IngelheimBristol-Myers SquibbCadila HealthcareCambridge Biotechnology Ltd.CASI PharmaceuticalsCatabasis PharmaceuticalsCelltex Therapeutics Corp.Celltrion, Inc.ChemoCentryxChugai Pharmaceutical Co., Ltd.Coherus BioSciences IncCovagen AGCyclacel PharmaceuticalsCyxone ABDaiichi SankyoDePuy SynthesDr Reddy's LaboratoriesEli LillyEpirus BiopharmaceuticalsFive Prime TherapeuticsFresenius KabiFujifilm CorporationGalapagos NVGaldermaGenentechGerresheimerGiaconda Ltd.Gilead Sciences, Inc.GlaxoSmithKline plcGlenmark Pharmaceuticals Ltd.Hanmi Pharmaceutical Co Ltd.HospiraImmunomedicsIncyte CorporationInnate Pharma - IPO PendingIntasItalfarmaco SpAIzana Bioscience Ltd.Janssen BiologicsJohnson & JohnsonKadmon HoldingsKyowa Hakko Kirin Co LtdLycera CorporationMedigeneMerck & Co.MesoblastMitsubishi Tanabe PharmaMomentaMorphosysMycenax BiotechMylan NVNeovacs SANeuBase Therapeutics, Inc.Novo NordiskOnyx Pharmaceuticals, Inc.OphthaliX, Inc. Can-Fite BioPharma LtdOutlook Therapeutics, Inc.PadlockPfizerPhilogen SpAPrincipia Biopharma, Inc.Protalex, Inc.Protalix BioTherapeuticsRa Pharmaceuticals Inc.Regeneron Pharmaceuticals, Inc.RocheSamsung BioepisSanofiShanghai CP Guojian PharmaceuticalsSpirig Pharma A.G.Takeda PharmaceuticalsTheravance Biopharma, Inc.TiGenix NV Takeda PharmaceuticalUCBVitaeris Inc,XencorXOMAZynerba Pharmaceuticals

Other Organisations Mentioned in the ReportAmerican College of RheumatologyNurses HealthWHONational Rheumatoid Arthritis SocietyUnited NationsUS Patent OfficeEuropean CommissionU.S. Food and Drug Administration (FDA)Committee for Medicinal Products for Human Use (CHMP)Centers for Disease Control and Prevention (CDC)World BankArthritis FoundationCanadian Arthritis SocietyWorld Arthritis DayNational Rheumatoid Arthritis SocietyServizio Sanitario Nazionale (SSN)Ministry of HealthNational Institute on AgingNational Center for Biotechnology InformationUnified Health SystemANVISA (Agncia Nacional de Vigilncia Sanitria)African League of Associations in RheumatologyInternational League of Associations for RheumatologyGovernment of Abu DhabiJohns HopkinsBumrungradCleveland ClinicVamedEmirates Arthritis FoundationNational Treasury of Republic of South AfricaEuropean Medicines AgencyNational Institute for Health Research (NIHR)National Institute for Health and Care Excellence (NICE)Institute for Quality and Efficiency in HealthcareInstitut fr Qualitt und Wirtschaftlichkeit im Gesundheitswesen IQWiG

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Bioreactors Market 2020-2030

Next-Generation Biologics Market Forecast to 2029

Global Biosimilars and Follow-On Biologics Market 2019-2029

Pharma Wholesale and Distribution Market Forecasts 2020-2030

Translational Regenerative Medicine Market Forecast 2020-2030

View original content:http://www.prnewswire.com/news-releases/visiongain-report-global-rheumatoid-arthritis-drugs-market-estimated-to-grow-at-a-cagr-of-0-6-in-the-second-half-of-the-forecast-period-301022961.html

SOURCE Visiongain

Read more:
Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Period - Yahoo...

Read More...

RHEUMATOID ARTHRITIS MARKET size Surge at a Robust Pace in Terms of Revenue over 2027 – Packaging News 24

Saturday, March 21st, 2020

Report Description

A recent market intelligence report that is published by Data Insights Partner on theglobal Rheumatoid Arthritis marketmakes an offering of in-depth analysis of segments and sub-segments in the regional and international Rheumatoid Arthritis market. The research also emphasizes on the impact of restraints, drivers, and macro indicators on the regional and global Rheumatoid Arthritis market over the short as well as long period of time. A detailed presentation of forecast, trends, and dollar values of global Rheumatoid Arthritis market is offered. In accordance with the report, the global Rheumatoid Arthritis market is projected to expand at a CAGR of 5% over the period of forecast.

Market Insight, Drivers, Restraints& Opportunity of the Market:

Rheumatoid arthritis is an autoimmune disease which can cause inflammation and pain in joints throughout the body. There are several types of diagnosis available for rheumatoid arthritis such as rheumatoid factor test, antinuclear antibody test, C-reactive protein test, erythrocyte sedimentation rate etc. Although there is no specific treatment available for cure of rheumatoid arthritis, some treatment help the patients to control this chronic disorder.

The global Rheumatoid Arthritis market is primarily driven by the increasing new cases of rheumatoid arthritis across worldwide. Around 1% of the world population has been suffering from rheumatoid arthritis whereas almost 3 new cases of rheumatoid arthritis per 10,000 population per year has been documented in 2018. In addition to increasing new cases of rheumatoid arthritis across worldwide, high diagnosis and treatment rate would likely to drive the global Rheumatoid Arthritis Market in the upcoming future. On the contrary, the stringent regulatory landscape and side effects of medications would likely to hamper the growth of the global Rheumatoid Arthritis market during the forecast period.

However, increasing expenditure in research and development, strategic alliance among key players and ongoing clinical trials may provide the global Rheumatoid Arthritis Market an opportunity to propel during the forecast period. For instance, Abbvie, a market leader in the global Rheumatoid Arthritis market acquired another pharmaceutical stalwart Allergan by US$ 63 Bn in June 2019. The acquisition would likely to boost the market position of Abbvie in the global Rheumatoid Arthritis market in upcoming future.

Request Preview of Report as Sample before Purchasing (For More Precedence Use Corporate email ID) :https://datainsightspartner.com/request-for-sample?ref=43

Segment Covered:

This market intelligence report on the global Rheumatoid Arthritis market encompasses market segments based on drug type and distribution channel. On the basis of drug type, the sub-market is categorized into NSAIDs, Analgesics, DMARDs, Glucocorticoids, Biologics, and Others. Based on distribution channel, the global Rheumatoid Arthritis market has been segregated into hospital pharmacies, retail pharmacies and drug stores and online sales. By Geography, the global Rheumatoid Arthritis market has been divided into North America (the U.S., Canada), Latin America (Brazil, Mexico, Argentina and other countries), Europe (Germany, France, the U.K., Spain, Italy, Russia, and other countries), Asia Pacific (India, Japan, China, Australia and New Zealand and other countries), Middle East and Africa (GCC, South Africa, Israel and Other countries).

Profiling of Market Players:

This business intelligence report offers profiling of reputed companies that are operating in the market. Companies such as AbbVie, Inc., Janssen Biotech, Inc., Amgen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company etc. have been profiled into detail so as to offer a glimpse of the market leaders. Moreover, parameters such as Rheumatoid Arthritis related investment & spending and developments by major players of the market are tracked in this global report.

Request for Report TOC:https://datainsightspartner.com/report/rheumatoid-arthritis-market/43#content

Report Highlights:

In-depth analysis of the micro and macro indicators, market trends, and forecasts of demand is offered by this business intelligence report. Furthermore, the report offers a vivid picture of the factors that are steering and restraining the growth of this market across all geographical segments. In addition to that, IGR-Growth Matrix analysis is also provided in the report so as to share insight of the investment areas that new or existing market players can take into consideration. Various analytical tools such as DRO analysis, Porters five forces analysis has been used in this report to present a clear picture of the market. The study focuses on the present market trends and provides market forecast from the year 2017-2027. Emerging trends that would shape the market demand in the years to come have been highlighted in this report. A competitive analysis in each of the geographical segments gives an insight into market share of the global players.

Find more research reports onHealthcare Industry,By Data Insights Partner

Salient Features:

This study offers comprehensive yet detailed analysis of the Rheumatoid Arthritis market, size of the market (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the period of forecast: 2019 2027, taking into account 2018 as the base year

It explains upcoming revenue opportunities across various market segments and attractive matrix of investment proposition for the said market

This market intelligence report also offers pivotal insights about various market opportunities, restraints, drivers, launch of new products, competitive market strategies of leading market players, emerging market trends, and regional outlook

Profiling of key market players in the world Rheumatoid Arthritis market is done by taking into account various parameters such as company strategies, distribution strategies, product portfolio, financial performance, key developments, geographical presence, and company overvie

Leading market players covered this report comprise names such as AbbVie, Inc., Janssen Biotech, Inc., Amgen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company. and among others

The data of this report would allow management authorities and marketers of companies alike to take informed decision when it comes to launch of products, government initiatives, marketing tactics and expansion, and technical up gradation

The world market for Rheumatoid Arthritis caters to the needs of various stakeholders pertaining to this industry, namely suppliers, manufacturers, investors, and distributors for Rheumatoid Arthritis market. The research also caters to the rising needs of consulting and research firms, financial analysts, and new market entrants

Research methodologies that have been adopted for the purpose of this study have been clearly elaborated so as to facilitate better understanding of the reports

Reports have been made based on the guidelines as mandated by General Data Protection Regulation

Ample number of examples and case studies have been taken into consideration before coming to a conclusion

Reasons to buy:

vIdentify opportunities and plan strategies by having a strong understanding of the investment opportunities in the Rheumatoid Arthritis market

vIdentification of key factors driving investment opportunities in the Rheumatoid Arthritis market

vFacilitate decision-making based on strong historic and forecast data

vPosition yourself to gain the maximum advantage of the industrys growth potential

vDevelop strategies based on the latest regulatory events

vIdentify key partners and business development avenues

vRespond to your competitors business structure, strategy and prospects

vIdentify key strengths and weaknesses of important market participants

Request for Report Analysis:https://datainsightspartner.com/report/rheumatoid-arthritis-market/43

See the original post:
RHEUMATOID ARTHRITIS MARKET size Surge at a Robust Pace in Terms of Revenue over 2027 - Packaging News 24

Read More...

Understanding acute and chronic inflammation – Harvard Health

Saturday, March 21st, 2020

The right kind of inflammation is essential to your body's healing system. But chronic inflammation can be a problem.

Published: April, 2020

The saying "too much of a good thing" applies to much of life, but especially to inflammation.

"People think inflammation needs to be stomped out at all times, but it plays an essential role in healing and injury repair to keep your body safe and healthy," says Dr. Robert H. Shmerling, medical editor of Understanding Inflammation from Harvard Health Publishing and an associate professor of medicine at Harvard Medical School. "Some inflammation is good. Too much is often bad. The goal is to recognize when inflammation is simply doing its job, and when it can potentially cause problems."

Signs of inflammation are like a car's dashboard engine light. It tells you that something is wrong. But your response is not to take out the bulb, because that's not the problem. Instead, you look at what caused the light to turn on. "It's the same with inflammation," says Dr. Shmerling. "It's telling you that something bigger is going on that requires attention."

There are two types of inflammation: acute and chronic. People are most familiar with acute inflammation. This is the redness, warmth, swelling, and pain around tissues and joints that occurs in response to an injury, like when you cut yourself. When the body is injured, your immune system releases white blood cells to surround and protect the area.

"Acute inflammation is how your body fights infections and helps speed up the healing process," says Dr. Shmerling. "In this way, inflammation is good because it protects the body." This process works the same if you have a virus like a cold or the flu.

In contrast, when inflammation gets turned up too high and lingers for a long time, and the immune system continues to pump out white blood cells and chemical messengers that prolong the process, that's known as chronic inflammation. "From the body's perspective, it's under consistent attack, so the immune system keeps fighting indefinitely," says Dr. Shmerling.

When this happens, white blood cells may end up attacking nearby healthy tissues and organs. For example, if you are overweight and have more visceral fat cells the deep type of fat that surrounds your organs the immune system may see those cells as a threat and attack them with white blood cells. The longer you are overweight, the longer your body can remain in a state of inflammation.

Research has shown that chronic inflammation is associated with heart disease, diabetes, cancer, arthritis, and bowel diseases like Crohn's disease and ulcerative colitis.

Yet, because chronic inflammation can continue for a long time, it's not easy to know its exact impact. "It's a chicken-and-egg scenario," says Dr. Shmerling. "Does chronic inflammation increase the risk of these ailments, or is it a byproduct? It is not always clear."

Here are some other steps you can take to prevent and reduce chronic inflammation:

Most of the time, you don't need to worry too much about acute inflammation, says Dr. Shmerling. You can take an over-the-counter pain reliever to help relieve symptoms, or apply cold compresses to reduce swelling. "Otherwise, it is usually best to let the inflammation do its work to help with healing," says Dr. Shmerling.

Of course, the cause of acute inflammation may need treatment. For example, a bacterial infection may require antibiotics, so if you have a fever or significant symptoms such as severe pain or shortness of breath see your doctor.

Chronic inflammation is trickier to deal with. The problem is that chronic inflammation is often "invisible," since it does not show telltale physical signs the way acute inflammation does.

So how can you prevent or reduce inflammation you cannot necessarily see or feel?

The only way to detect chronic inflammation is to have an evaluation by your doctor. He or she will review your symptoms, perform a physical exam, and perhaps check your blood for signs of inflammation. (See "A test for inflammation.")

Otherwise, the best approach is to prevent conditions related to chronic inflammation. "It goes back to the basics: maintaining a healthy weight, choosing a good diet, getting plenty of sleep, and exercising regularly," says Dr. Shmerling.

How do you know if you have chronic inflammation? A blood test measures a protein produced by the liver, C-reactive protein (CRP), which rises in response to inflammation. A CRP level between 1 and 3 milligrams per liter of blood often signals a low, yet chronic, level of inflammation. The erythrocyte sedimentation rate is another blood test for inflammation. It is used for people with inflammatory conditions, like rheumatoid arthritis.

Diet and exercise have an especially strong impact on managing chronic inflammation since they both also can help control weight and improve sleep.

The evidence is not clear that a specific type of diet can prevent chronic inflammation. However, certain foods are associated with either promoting or inhibiting the inflammatory response. These foods also are linked to a lower risk of problems related to chronic inflammation, such as heart disease, weight gain, and cancer.

For instance, cut back or eliminate foods high in simple sugars like soda, fruit juices with added sugars, sports drinks, processed meat, and refined carbs like white bread and pasta. "These foods can spike blood sugar levels, which can lead to overeating and weight gain," says Dr. Shmerling.

Also, eat more foods high in the antioxidants known as polyphenols, which can lower inflammation. Examples include all types of berries, cherries, plums, red grapes, onions, turmeric, green tea, and dark green leafy vegetables like spinach and kale.

Regular exercise can help protect against conditions linked with chronic inflammation, especially heart disease and obesity. A 2017 study in Brain, Behavior, and Immunity found that just 20 minutes of moderate-intensity exercise (in this case, walking on a treadmill) can have an anti-inflammatory effect.

Image: Mingirov/Getty Images

Disclaimer:As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

The rest is here:
Understanding acute and chronic inflammation - Harvard Health

Read More...

New Research Among People Living With Rheumatoid Arthritis Reveals Key Determinants Of Patient Satisfaction With Doctors – Monterey County Weekly

Friday, March 20th, 2020

SAN FRANCISCO, March 20, 2020 /PRNewswire/ --MyHealthTeams, creator of the largest and fastest-growing social networks for people facing chronic health conditions, today unveiled new research conducted among registered members of myRAteam, the social network for people living with rheumatoid arthritis (RA). Key findings spanned topics including patient satisfaction with their doctors, the impact RA has on quality of life, and common symptoms and flare-up triggers.

"Joint pain is just the tip of the iceberg for those living with rheumatoid arthritis. You've got to treat the whole person, not just their obvious symptoms," said Eric Peacock, cofounder and CEO of MyHealthTeams. "RA patients in this research made it clear that the best rheumatologists are those who take the time to truly understand the full range of symptoms and the quality of life impact people with RA are experiencing. The gap between patients satisfied and dissatisfied with their doctors was stark."

Patient Satisfaction: Determined by listening/understanding, time spent, and breadth of discussionThere is a high correlation between treatment satisfaction and doctor satisfaction, so if treatment isn't working to control a patient's RA, it's unlikely she will be satisfied with her doctor. But treatment effectiveness isn't the only driver. The study revealed a significant experience gap between those who are satisfied or not with their doctors. Among the 57% of RA patients who report overall satisfaction with their doctors: 87% feel their doctor listens to them and understands their needs; 81% believe their doctor spends enough time with them; 74% report their doctor addresses symptoms such as pain, depression and anxiety; 65% discuss treatment side effects with their doctor; and 52% say their doctor has worked with them to develop a long-term plan. Among the 43% of RA patients who report overall dissatisfaction with their doctors, these numbers drop to 24%, 26%, 20%, 29% and 12% respectively.

Impact on Quality of Life: Daily challenges and emotional impacts take toll at home, work and beyond RA, a chronic inflammatory condition in which the body's immune system attacks its own tissue, including joints, has wide-ranging impact on quality of life.

Further, the emotional toll of RA is significant.

Symptoms and Triggers: Aggravated by environmental factors, disease causes symptoms well beyond joint pain and stiffnessBeyond the joint pain and stiffness experienced by nearly everyone surveyed, myRAteam members report a broad spectrum of symptoms, including:

The top reported triggers for flare-ups of RA symptoms are stress (79%) and cold weather (73%).

This research was conducted among registered members of myRAteam. 374 individuals responded to the online survey. Full survey findings are available at https://www.myrateam.com/resources/the-results-are-in-people-living-with-rheumatoid-arthritis-are-more-satisfied-with-their-doctors-when-they-feel-heard-and-understood

About MyHealthTeamsMyHealthTeamsbelieves that if you are diagnosed with a chronic condition, it should be easy to find and connect with others like you. MyHealthTeams creates social networks for people living with a chronic health condition. Millions of people have joined one of the company's 35 highly engaged communities focusing on the following conditions: Crohn's and colitis, multiple sclerosis, lupus, fibromyalgia, pulmonary hypertension, spondylitis, eczema, myeloma, hyperhidrosis, vitiligo, rheumatoid arthritis, psoriasis, leukemia, lymphoma, irritable bowel syndrome, Parkinson's, Alzheimer's, epilepsy, hemophilia, hidradenitis suppurative, depression, heart disease, type 2 diabetes, osteoporosis, COPD, chronic pain, migraines, food allergies, obesity, HIV, PCOS, endometriosis, breast cancer and autism. MyHealthTeams' social networks are available in 13 countries.

Read this article:
New Research Among People Living With Rheumatoid Arthritis Reveals Key Determinants Of Patient Satisfaction With Doctors - Monterey County Weekly

Read More...

Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial – DocWire…

Friday, March 20th, 2020

INTRODUCTION:

The objective of this study was to assess efficacy and safety of repository corticotropin injection (RCI) in subjects with activerheumatoid arthritis(RA) despite treatment with a corticosteroid and one or two disease-modifying antirheumatic drugs (DMARDs).

All subjects received open-label RCI (80 U) twice weekly for 12weeks (part 1); only those with low disease activity [LDA; i.e., Disease Activity Score 28 joint count and erythrocyte sedimentation rate (DAS28-ESR)<3.2] were randomly assigned to receive either RCI (80 U) or placebo twice weekly during the 12-week double-blind period (part 2). The primary efficacy endpoint was the proportion of subjects who achieved LDA at week 12. Secondary efficacy endpoints included proportions of subjects who maintained LDA during weeks 12 through 24 and achieved Clinical Disease Activity Index (CDAI)10 at weeks 12 and 24. Safety was assessed via adverse event reports.

Of the 259 enrolled subjects, 235 completed part 1; 154 subjects (n=77 each for RCI and placebo) entered part 2, and 127 (RCI, n=71; placebo, n=56) completed. At week 12, 163 subjects (62.9%) achieved LDA and 169 (65.3%) achieved CDAI10 (both p<0.0001). At week 24, 47 (61.0%) RCI-treated and 32 (42.1%) placebo-treated subjects maintained LDA (p=0.019); 66 (85.7%) RCI-treated and 50 (65.8%) placebo-treated subjects maintained CDAI10 (p=0.004). No unexpected safety signals were observed.

RCI was effective and generally safe in patients with active RA despite corticosteroid/DMARD therapy. By week 12,>60% of patients achieved LDA, which was maintained with 12 additional weeks of treatment. Most patients who achieved LDA maintained it for 3months after RCI discontinuation.

Clinicaltrials.gov identifierNCT02919761.

See more here:
Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial - DocWire...

Read More...

Relationship between disease activity of rheumatoid arthritis and development of locomotive syndrome: A five-year longitudinal cohort study – DocWire…

Friday, March 20th, 2020

OBJECTIVE:

This study aimed to longitudinally evaluate the association betweenrheumatoid arthritis(RA) and locomotive syndrome (LS) in RA patients using the 25-question Geriatric Locomotive Function Scale (GLFS-25).

Subjects were 58 RA patients (female, 48 (82.8%); mean age, 60.910.9 years) who had GLFS-25 scores available for five consecutive years and who did not have LS at baseline (i.e., GLFS-25<16 points). Associations between DAS28-CRP and the development of LS were determined using linear regression analysis and receiver operating characteristic (ROC) curve analysis.

Subjects were divided into the LS group (n=15, GLFS-2516 points) and Non-LS group (n=43, GLFS-25<16 points) based on GLFS-25 scores at the 5th year of the study period. In the LS group, DAS28-CRP worsened every year. The linear regression model adjusted for age and sex revealed that GLFS-25 increased by 3.80 (95% confidence interval: 1.81-5.79) each time DAS28-CRP increased by 1 (p<0.001). Among patients in remission (DAS28-CRP <2.3), 13.5% had LS. ROC curve analysis yielded a five-year mean DAS28-CRP of 1.99 (sensitivity, 86.7%; specificity, 62.8%) as the cut-off point for the development of LS.

Tight control of RA disease activity for deeper remission may be needed to prevent the development of LS.

Read the rest here:
Relationship between disease activity of rheumatoid arthritis and development of locomotive syndrome: A five-year longitudinal cohort study - DocWire...

Read More...

Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices -…

Friday, March 20th, 2020

OBJECTIVE:

The aim of this study was to evaluate the discriminant capability of the Patient Acceptable Symptom State (PASS) according to disease activity, remission/low disease activity indices and quality of life indices in patients withpsoriatic arthritis(PsA).

Consecutive patients with PsA were enrolled in this cross-sectional study. At each visit, the patients underwent a complete physical examination and their clinical/laboratory data were collected. Disease activity was assessed using the Disease Activity Score forPsoriatic Arthritis(DAPSA) and remission/low disease activity using the DAPSA minimal disease activity (MDA) and very low disease activity (VLDA) criteria. ThePsoriatic ArthritisImpact of Disease (PsAID) and the Health Assessment Questionnaire-Disability Index scores were also collected. Finally, PASS was assessed by asking all patients to answer yes or no to a single question.

Patients who answered yes to PASS showed a significantly better overall mean DAPSA score than those who were not in PASS. Furthermore, patients in PASS showed a significantly lower level of systemic inflammation, lower Leeds Enthesitis Index score, a significantly lower impact of disease (PsAID), lower pain and better function than patients who answered no to PASS. A moderate to good agreement was found between PASS, MDA, DAPSA low disease activity and PsAID score 4. Good sensitivity and specificity were found with PASS with respect to DAPSA low disease activity, and although PASS is sensitive in the identification of patients with MDA, DAPSA remission and VLDA it lacks of specificity.

This study showed that PASS might be used as an alternative to determine disease activity in patients with PsA in real clinical practice, mainly in patients with low disease activity according to DAPSA criteria.

Read this article:
Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices -...

Read More...

FDA Approves OTC Combination of Ibuprofen and Acetaminophen for Minor Arthritis Pain – Rheumatology Advisor

Friday, March 20th, 2020

Home Topics Pain Management

The FDA has approved Advil Dual Action with Acetaminophen (GlaxoSmithKline), the first over-the-counter (OTC) fixed-dose combination therapy containing ibuprofen and acetaminophen for the temporary relief of minor aches and pains due to headache, backache, muscular aches, toothache, menstrual cramps, and minor pain of arthritis.

Each caplet contains 125mg of Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) and 250mg of acetaminophen and is indicated for adults and children 12 years of age and older. The approval was based on study data that showed use of the fixed-dose combination therapy was associated with superior pain relief compared with the individual components taken alone.

Advil Dual Action with Acetaminophen is expected to be available nationwide sometime during 2020.

GlaxoSmithKline recently received FDA approval for another OTC pain reliever, Voltaren Arthritis Pain (diclofenac topical gel), for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults 18 years old. The OTC formulation is the same as the prescription strength (10mg of diclofenac sodium per gram or 1%). It is expected to be available in spring 2020.

For more information visit gsk.com.

This article originally appeared on MPR

Please login or register first to view this content.

LoginRegister

Next post in Pain ManagementClose

Go here to see the original:
FDA Approves OTC Combination of Ibuprofen and Acetaminophen for Minor Arthritis Pain - Rheumatology Advisor

Read More...

Rheumatoid Arthritis Treatment Market Share, Size, Future Demand, Global Research, Top Leading Player, Emerging Trends and Forecast to 2029 – Daily…

Friday, March 20th, 2020

The Rheumatoid Arthritis Treatment Market study offers an in-depth analysis of the current market trends influencing this business vertical. The study also includes market valuation, market size, revenue forecasts, geographical spectrum and SWOT Analysis of the industry. In addition, the report depicts key challenges and growth opportunities faced by the industry bigwigs, in consort with their product offerings and business strategies.

A collective analysis of Rheumatoid Arthritis Treatment Market offering an exhaustive study based on current trends influencing this vertical across various geographies has been provided in the report. Also, this research study estimates this space to accrue considerable income during the projected period, with the help of a plethora of driving forces that will boost the industry trends during the forecast duration. Snippets of these influences, in tandem with countless other dynamics relating to the Rheumatoid Arthritis Treatment Market, like the risks that are predominant across this industry along with the growth prospects existing in Rheumatoid Arthritis Treatment Market, have also been charted out in the report.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/2263

The report covers exhaustive analysis on:

Regional analysis includes

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/2263

The report provides extensive data concerning the market share that each one of these companies presently gather throughout this business, followed by the market share that they are anticipated to acquire by the end of the predicted timeframe. Also, the report expounds on details relating to the goods manufactured by these firms, that would help new industry participants and major stakeholders work on their competition and portfolio strategies. In addition, their policymaking process is likely to get easier since the Rheumatoid Arthritis Treatment Market report also enumerates an idea of the trends in product prices and the revenue margins of all the major companies partaking in the industry share.

Queries that the Rheumatoid Arthritis Treatment Market report answers in respect of the regional landscape of the business domain:

Get Full Report Access athttps://www.xploremr.com/cart/2263/SL

Significant takeaways from the study:

The Rheumatoid Arthritis Treatment Market report hosts excess deliverables that may be highly advantageous. Say for instance, the report emphasizes information regarding market competition trends extremely essential data subject to contender intelligence and the current industry drifts that would enable shareholders to compete and take advantage of the biggest growth opportunities in the Rheumatoid Arthritis Treatment Market.

Another vital takeaway from the report can be accredited to the industry concentration rate that could help stakeholders to speculate on the existing sales dominance and the probable trends of the forthcoming years.

Additional deliverables mentioned in the report include details pertaining to the sales channels deployed by prominent sellers in order to retail their status in the industry, including direct and indirect marketing.

About Us

XploreMR is one of the worlds leading resellers of high-quality market research reports. We feature in-depth reports from some of the worlds most reputed market research companies and international organizations. We serve across a broad spectrum from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.

Contact us:

XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108E-mail id-[emailprotected]Web-https://www.xploremr.com

Read the original:
Rheumatoid Arthritis Treatment Market Share, Size, Future Demand, Global Research, Top Leading Player, Emerging Trends and Forecast to 2029 - Daily...

Read More...

Rheumatoid Arthritis Diagnosis Tests Market expected to Witness a Sustainable Growth over 2017 2025 – Feed Road

Friday, March 20th, 2020

Rheumatoid Arthritis Diagnosis Tests Market size will reach xx million US$ by 2029, from xx million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and2017 2025 as the forecast period to estimate the market size for Rheumatoid Arthritis Diagnosis Tests.

This industry study presents the Rheumatoid Arthritis Diagnosis Tests Market size, historical breakdown data 2014-2019 and forecast 2017 2025. The Private Plane production, revenue and market share by manufacturers, key regions and type; The consumption of Rheumatoid Arthritis Diagnosis Tests Market in volume terms are also provided for major countries (or regions), and for each application and product at the global level.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/336

Rheumatoid Arthritis Diagnosis Tests Market report coverage:

The Rheumatoid Arthritis Diagnosis Tests Market report covers extensive analysis of the market scope, structure, potential, fluctuations, and financial impacts. The report also enfolds the precise evaluation of market size, share, product & sales volume, revenue, and growth rate. It also includes authentic and trustworthy estimations considering these terms.

The Rheumatoid Arthritis Diagnosis Tests Market has been reporting substantial growth rates with considerable CAGR for the last couple of decades. According to the report, the market is expected to grow more vigorously during the forecast period and it can also influence the global economic structure with a higher revenue share. The market also holds the potential to impact its peers and parent market as the growth rate of the market is being accelerated by increasing disposable incomes, growing product demand, changing consumption technologies, innovative products, and raw material affluence.

The study objectives are Rheumatoid Arthritis Diagnosis TestsMarket Report:

In this study, the years considered to estimate the market size of Rheumatoid Arthritis Diagnosis TestsMarket:

History Year: 2014 2018

Base Year: 2018

Estimated Year: 2019

Forecast Year:2017 2025

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Rheumatoid Arthritis Diagnosis Tests Market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/336

The report covers exhaustive analysis on:

Regional analysis includes

Get Full Report Access athttps://www.xploremr.com/cart/336/SL

Benefits of Purchasing from XMR:

About Us

XploreMR is one of the worlds leading resellers of high-quality market research reports. We feature in-depth reports from some of the worlds most reputed market research companies and international organizations. We serve across a broad spectrum from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.

Contact us:

XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108E-mail id-[emailprotected]Web-https://www.xploremr.com

Read the original here:
Rheumatoid Arthritis Diagnosis Tests Market expected to Witness a Sustainable Growth over 2017 2025 - Feed Road

Read More...

Fight Inflammation With Tart Cherry Juice – Newsmax

Friday, March 20th, 2020

Tart cherry juice is the latest health rage and for good reason. The cancer-fighting beverage may also protect against heart disease, reduce arthritis symptoms, and help you sleep more soundly.

"Tart cherries are loaded with important nutrients, but you'd have to eat an entire bag of them to obtain all the benefits you get by sipping the juice," says Michele Turcotte, M.S., R.D., a dietitian and nutritionist in Lake Geneva, Wisconsin. "Its juice contains many antioxidants and anti-inflammatory agents, which can help alleviate a variety of ailments like asthma symptoms and pain."

Turcotte explains that tart cherries, like all red fruits and vegetables, are rich in anthocyanins, a particularly potent antioxidant phytochemical.

"Anthocyanins encourage healthy circulation, ensure proper nerve function, and offer cancer-fighting properties," says the expert. A research study published in the Journal of Nutrition says that tart cherry juice provides older adults great protection against the development of heart disease, cancer and age-related cognitive decline.

Here are more health benefits:

* Heart disease and diabetes. The quercetin found in tart cherry juice is another powerful antioxidant that helps prevent free radical damage caused by low-density lipoprotein or LDL, according to a 2013 study. When LDL cholesterol is oxidized, its more likely to stick to arterial walls, forming plaque that contributes to heart attack and stroke.

Another study published in the International Journal of Preventative Medicine noted that intake of high levels of quercetin were associated with reduced risk of type 2 diabetes.

* Insomnia. Drinking an 8-ounce glass of tart cherry juice in the morning and the evening may be a better and safer way to treat insomnia than taking drugs, according to researchers at Louisiana State University. Tart cherries are a natural source of melatonin, a hormone that helps regulate the sleep-wake cycle.

* Sports recovery and muscle damage. Marathon runners who consumed 8 ounces of tart cherry juice twice daily for five days prior to a marathon, on the day of the marathon, and then for two days afterward reported less muscle damage, soreness, inflammation, and protein breakdown than runners who consumed a placebo, according to research published in the Scandinavian Journal of Medicine and Science in Sports.

* Arthritis and gout. Tart cherry juice may reduce arthritis symptoms such as joint pain and inflammation, according to several studies. A 2012 study revealed that folks with osteoarthritis who drank tart cherry juice for 21 days had reduced symptoms of pain.

* Brain health. Since degenerative brain disorders like Parkinson's and Alzheimer's are thought to be causeed, in part, by oxidative stress, drinking tart cherry juice may have protective effects on brain cells. In fact, in one study, older adults with mild-to-moderate cognitive decline consumed 6 ounces of tart cherry juice daily or a placebo for 12 weeks. The adults in the tart cherry juice group experienced improvement in verbal fluency, short term memory, and long-term memory, whereas the placebo group experienced no improvement.

2020 NewsmaxHealth. All rights reserved.

Read the rest here:
Fight Inflammation With Tart Cherry Juice - Newsmax

Read More...

Regeneron to treat coronavirus patients this week in trial using its rheumatoid arthritis drug – CNBC

Thursday, March 19th, 2020

Regeneron Pharmaceuticals this week initiated test trials of an arthritis drug as a potential remedy for the worst symptoms of COVID-19, the disease caused by the novel coronavirus.

The biotech giant announced Monday it launched a clinical program using Kevzara, a commercial medicine that treats active rheumatoid arthritis, and recruiting hospitalized patients experiencing severe symptoms of the respiratory illness.

"We did something that's never been done in record time," launching a study in New York state "where we're going to already be treating patients with this," Regeneron Chief Scientific Officer Dr. George Yancopoulos told CNBC'sJim Crameron Tuesday.

The Regeneron co-founder and president hopes within a few weeks that results will support findings from China, where health officials tried a variety of medicines to combat the disease as the virus spread quickly. Kevzara is an antibody that could help prevent the lungs from triggering an overactive inflammatory response, Regeneron said.

"The one thing everybody got excited about is something that blocked inflammation. This was done in an uncontrolled way, not a randomized controlled study," Yancopoulos said in the "Mad Money" interview.

Regeneron is working with the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority to get the trials underway, he added.

If successful, it could be used as an immediate remedy for patients in critical condition.

"[W]e're going to be hopefully seeing within a few weeks whether this really replicates and confirms the positive suggestions that are coming out of China,"Yancopoulos said. "If they are, it means for the most seriously ill patients we may have something that keeps them from having to go on ventilators or be able to maybe take off ventilators."

Regeneron is working on the clinical program with Sanofi, the French drugmaker leading the study abroad. The biotech companies co-developed Kevzara, which received FDA approval in 2017.

The U.S. trial will launch in medical centers in New York, the state hardest hit by the coronavirus pandemic, and is expected to enroll as many as 400 patients in more than a dozen states. The second phase of the program will study long-term outcomes, according to a press release.

"This could in a very short time give hope to the most critical people,"Yancopoulos said.

Outside of the Kevzara trial, Regeneron announced Tuesday it plans to begin testing a coronavirus antibody treatment on humans sooner than once expected. The company moved its timeline up for human testing from late summer to early summer.

There are more than 7,300 confirmed cases in the United States as of Wednesday afternoon, according to data compiled by Johns Hopkins University.

Read the original post:
Regeneron to treat coronavirus patients this week in trial using its rheumatoid arthritis drug - CNBC

Read More...

Here are some of the existing drugs that may be repurposed to treat coronavirus – NBCNews.com

Thursday, March 19th, 2020

Pharmaceutical companies and research facilities are working to find new, successful treatments for those infected with coronavirus. But clinical trials and FDA approval can take time, so while new drugs are being developed, companies are seeing if older drugs can be repurposed.

Heres a list of some of the options being explored and why they might be useful in blunting the effects of coronavirus.

Doctors in China have used an anti-inflammation drug to curb the effects of the coronavirus on critical patients, and now the maker of the drug says it is talking to the Food and Drug Administration about clinical trials.

Tocilizumab, sold under the name Actemra and made by the Swiss pharmaceutical firm Roche, is a prescription medicine used to treat adults with moderate to severe active rheumatoid arthritis, as well as certain types of juvenile arthritis.

Chinese doctors have used Tocilizumab to prevent an overreaction of the immune system that has led to organ failure and death in coronavirus patients. An initial clinical trial in China used Actemra in 20 severe COVID-19 cases. Nineteen of the patients were discharged from the hospital within two weeks and one got better, according to Chinas National Health Commission. The drug has now been approved for use in China, but has not yet been approved in the United States.

Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.

Karsten Kleine, a spokesperson for Roche, told NBC News that the drug company is in active discussions with the FDA, as well as government bodies and institutions around the world, to initiate clinical trials that evaluate the safety and efficacy of Actemra (tocilizumab) for the treatment of severely ill COVID-19 patients.

Roche is not alone in looking into rheumatoid arthritis drugs as a potential treatment. Sanofi and Regeneron are launching a clinical trial in New York to see if their rheumatoid arthritis drug Kevzara is effective.

AbbVie, the creator of HIV drugs Kaletra/Aluvia, is collaborating with health authorities to determine the efficacy of using its HIV drugs to treat COVID-19. The company is working with the FDA, CDC, and European agencies to set up clinical trials of the drug.

At this time, AbbVie told NBC News it cannot confirm Chinese media reports that the drug has been successful in treatment as it does not have access to Chinese clinical information. It is monitoring its current supply to make sure current HIV patients being treated by the drug will not be affected by an increase in demand.

Sanofi is assessing the risk and benefit of its malaria drug hydroxychloroquine for the management of coronavirus. According to the company, some health authorities are allowing the temporary use of chloroquine for the management of COVID-19, but there is insufficient data to draw any conclusions over its efficacy. Any use of the drug in this context is considered off-label use.

Based on encouraging preliminary findings from a study in France, Sanofi is looking at ways to collaborate and partner with health authorities investigating the use of hydroxychloroquine for the management of coronavirus.

Remdesivir is a broad spectrum anti-viral medication developed by Gilead Sciences as a treatment for Ebola and also showed success in treatment of monkeys infected with MERs, a different type of coronavirus. It is now being tested as a potential COVID-19 treatment.

Remdesivir is in clinical trials in China and the U.S. at the University of Nebraska Medical Center. There are 20 locations involved in the trial and seven are recruiting for participants, including Emory Vaccine Center in Atlanta and The University of Washington Virology Research Clinic. All participants must have laboratory-confirmed SARS-CoV-2 infection with symptoms showing evidence of lung involvement, rattling sounds when breathing with a need for supplemental oxygen or abnormal chest X-rays, or illness requiring mechanical ventilation.

The first participant is an American who was on the Diamond Princess cruise ship that docked in Yokohama, Japan.

Those with a confirmed infection who have mild symptoms or no apparent symptoms at all cannot participate in the study.

Emily Siegel is an associate producer with the NBC News Investigative Unit.

Originally posted here:
Here are some of the existing drugs that may be repurposed to treat coronavirus - NBCNews.com

Read More...

Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Period – P&T…

Thursday, March 19th, 2020

- Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030

- Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

LONDON, March 18, 2020 /PRNewswire/ -- The global Rheumatoid Arthritis market is estimated to have reached $58bn in 2018 and is expected to grow at a CAGR of 0.6% in the second half of the forecast period. In 2018, the biologics submarket held 85% of the global Rheumatoid Arthritis market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new236-page reportyou will receive180 tables and 121 figures all unavailable elsewhere.

The 236-page Visiongain report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/#download_sampe_div

Report Scope

Global Rheumatoid Arthritis Marketforecast from 2020-2030

Revenue forecasts for theRheumatoid Arthritis Market by Drug Classfrom 2020-2030: Biologics Non-Biologics: NSAIDs, sDMARDs, Others

Revenue forecasts for theRheumatoid Arthritis Market by Drugsfrom 2020-2030: Humira Enbrel Remicade Rituxan/MabThera Simponi/Simponi Aria Orencia Actemra/Roactemra Cimzia Celebrex Xeljanz Arcoxia Others

Revenue forecasts for theRheumatoid Arthritis Market by Regionfrom 2020-2029: North America: U.S., Canada Europe: Germany, UK, France, Italy, Spain, Russia, Rest of Europe Asia-Pacific: Japan, China, India, Rest of Asia-Pacific Latin America: Brazil, Mexico, Rest of Latin America Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA

Profiles of these selected leading companies: AbbVie Amgen, Inc. Bristol-Myers Squibb Eli Lilly and Company F. Hoffmann-La Roche Ltd Johnson & Johnson Merck & Co. Novartis AG Pfizer Sanofi S.A. UCB

Analysis of the Drivers, Restraints, Opportunities and Threats of the global rheumatoid arthritis drugs market

The report also includes SWOT Analysis of the Global rheumatoid arthritis drugs market

Key questions answered by this report: How is the Rheumatoid Arthritis drugs market evolving? What is driving and restraining the Rheumatoid Arthritis drugs market? What are the market shares of each segment of the overall Rheumatoid Arthritis drugs market in 2018? How will each Rheumatoid Arthritis drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030? How will the market shares for each Rheumatoid Arthritis drugs submarket develop from 2020 to 2030? Which individual therapies will prevail and how will these shifts be responded to? What will be the main driver for the overall market from 2020 to 2030? How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030? Who are the leading players and what are their prospects over the forecast period? How will the industry evolve during the period between 2020 and 2030?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

4SCAbbVieAbivaxAblynx NV SanofiAdheron Therapeutics, Inc.Akari Therapeutics PlcAlder BiopharmaceuticalsAmgenAnacorAraim Pharmaceuticals, Inc.argenxArtax Biopharma, Inc.Astellas Pharma IncBaxalta IncorporatedBiocon Ltd.BiogenBioxpress TherapeuticsBoehringer IngelheimBristol-Myers SquibbCadila HealthcareCambridge Biotechnology Ltd.CASI PharmaceuticalsCatabasis PharmaceuticalsCelltex Therapeutics Corp.Celltrion, Inc.ChemoCentryxChugai Pharmaceutical Co., Ltd.Coherus BioSciences IncCovagen AGCyclacel PharmaceuticalsCyxone ABDaiichi SankyoDePuy SynthesDr Reddy's LaboratoriesEli LillyEpirus BiopharmaceuticalsFive Prime TherapeuticsFresenius KabiFujifilm CorporationGalapagos NVGaldermaGenentechGerresheimerGiaconda Ltd.Gilead Sciences, Inc.GlaxoSmithKline plcGlenmark Pharmaceuticals Ltd.Hanmi Pharmaceutical Co Ltd.HospiraImmunomedicsIncyte CorporationInnate Pharma - IPO PendingIntasItalfarmaco SpAIzana Bioscience Ltd.Janssen BiologicsJohnson & JohnsonKadmon HoldingsKyowa Hakko Kirin Co LtdLycera CorporationMedigeneMerck & Co.MesoblastMitsubishi Tanabe PharmaMomentaMorphosysMycenax BiotechMylan NVNeovacs SANeuBase Therapeutics, Inc.Novo NordiskOnyx Pharmaceuticals, Inc.OphthaliX, Inc. Can-Fite BioPharma LtdOutlook Therapeutics, Inc.PadlockPfizerPhilogen SpAPrincipia Biopharma, Inc.Protalex, Inc.Protalix BioTherapeuticsRa Pharmaceuticals Inc.Regeneron Pharmaceuticals, Inc.RocheSamsung BioepisSanofiShanghai CP Guojian PharmaceuticalsSpirig Pharma A.G.Takeda PharmaceuticalsTheravance Biopharma, Inc.TiGenix NV Takeda PharmaceuticalUCBVitaeris Inc,XencorXOMAZynerba Pharmaceuticals

Other Organisations Mentioned in the ReportAmerican College of RheumatologyNurses HealthWHONational Rheumatoid Arthritis SocietyUnited NationsUS Patent OfficeEuropean CommissionU.S. Food and Drug Administration (FDA)Committee for Medicinal Products for Human Use (CHMP)Centers for Disease Control and Prevention (CDC)World BankArthritis FoundationCanadian Arthritis SocietyWorld Arthritis DayNational Rheumatoid Arthritis SocietyServizio Sanitario Nazionale (SSN)Ministry of HealthNational Institute on AgingNational Center for Biotechnology InformationUnified Health SystemANVISA (Agncia Nacional de Vigilncia Sanitria)African League of Associations in RheumatologyInternational League of Associations for RheumatologyGovernment of Abu DhabiJohns HopkinsBumrungradCleveland ClinicVamedEmirates Arthritis FoundationNational Treasury of Republic of South AfricaEuropean Medicines AgencyNational Institute for Health Research (NIHR)National Institute for Health and Care Excellence (NICE)Institute for Quality and Efficiency in HealthcareInstitut fr Qualitt und Wirtschaftlichkeit im Gesundheitswesen IQWiG

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Bioreactors Market 2020-2030

Next-Generation Biologics Market Forecast to 2029

Global Biosimilars and Follow-On Biologics Market 2019-2029

Pharma Wholesale and Distribution Market Forecasts 2020-2030

Translational Regenerative Medicine Market Forecast 2020-2030

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

Read more:
Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Period - P&T...

Read More...

DReSS Linked to High Fatality Lung Disease in Juvenile Idiopathic Arthritis – Monthly Prescribing Reference

Thursday, March 19th, 2020

After careful consideration, the American Academy of Allergy, Asthma & Immunology canceled its annual meeting that was to take place in Philadelphia, Pennsylvania from March 13 to 16, because of concerns regarding the coronavirus disease 2019 (COVID-19) outbreak. Although the live events will not proceed as planned, our readers can still find coverage of research that was scheduled to be presented at the meeting.

Drug reaction with eosinophilia and systemic symptoms (DReSS) with exposure to interleukin (IL)-1 or IL-6 inhibition may be linked to high fatality lung disease and poor outcomes in systemic juvenile idiopathic arthritis (sJIA), according to research intended to be presented at the American Academy of Allergy Asthma and Immunology (AAAAI) annual meeting.

Using REDCap databases, researchers collected retrospective observational data for 63 patients with sJIA with lung disease who were diagnosed by 55 physicians from 39 institutions. Researchers evaluated DReSS in patients by using the validated RegiSCAR scoring system.

Of the 63 patients with sJIA and lung disease, 48 had unusual high fatality lung disease associated with IL-1 or IL-6 inhibition. A total of 15 patients were scored with definite DReSS (score, >5/9) and 8 with probable DReSS (score, 4-5/9). At the time of eosinophilia diagnosis, all 23 patients had been exposed to 1 medications, including anakinra, tocilizumab, canakinumab, and rilonacept. Despite concurrent steroid treatment (0-2 mg/kg/d), median peak peripheral eosinophil count was 1725 (range, 754-13,156; 6%-45% of white blood cells) in patients with definite DReSS; facial rash with angioedema was reported in 12 patients.

Among patients in the definite DReSS group, 8 patients stopped the suspected medication, of whom 6 survived (median survival since lung disease diagnosis, 4.7 years) and 2 died after restarting the medication. The remaining 7 patients who continued the medication died.

Overall, the researchers concluded that, DReSS with lung involvement is a high fatality illness. Unrecognized DReSS with exposure to anti-IL-1/IL-6 may account for lung disease and poor outcome in some sJIA cases.

Reference

Saper V, Mellins E, Kwong B. Drug reaction and high fatality lung disease in systemic onset juvenile idiopathic arthritis (sJIA). J Allergy Clin Immunol. 2020;145(Suppl 2):AB95.

This article originally appeared on Pulmonology Advisor

Read more:
DReSS Linked to High Fatality Lung Disease in Juvenile Idiopathic Arthritis - Monthly Prescribing Reference

Read More...

They’re Back in the Game – HealthCentral.com

Thursday, March 19th, 2020

As anyone who lives with a chronic illness knows, the plans you have for your life cant always be counted on. Sometimes, theres no amount of trying that will ever be enough to meet those hoped-for goals. And sometimes, you have to let your body lead the way to a future your never imagined.

In 2010, Kirsten Schultz, now 31, was working on a masters degree in Islamic studies and Arabic language at the University of Wisconsin in Madison. Their ultimate goal? To make a difference in the world by working as a diplomat. (Schultz uses the pronoun they). And theyd gotten this far by sheer determination. Schultz had literally clawed their way through college, fighting symptoms of rheumatoid arthritis every step of the way. Not only did they work multiple jobs, Schultz battled frequent illnesses and disease flares. But by the time they began work on their graduate degree, new medication had gotten Schultzs symptoms mostly under controluntil they werent.

Like most treatments for RA, Schultzs medication works to suppress the overactive immune response thats causing the joint pain and inflammation; as a result, patients are often more vulnerable to infections. And during grad school, Schultz seemed to get anything and everything that was floating around campus.

Professors docked points when they missed classes, which happened frequently. Some days Schultz just couldnt get there. Daily Arabic classes really required near perfect attendance and missing even one day a week meant a lot of makeup work, Schultz explains. On weeks where I missed more than one day, I was honestly just a body in a classroom. Physically and emotionally, I felt like I was drowning.

Battling these illnesses on top of the fatigue, pain, and brain fog that was just part of living with their arthritis eventually made it almost impossible for Schultz to manage their course load. Something was going to have to change. After 18 months of struggling, they decided to withdraw from school in 2012.

Everything I had worked for for so long, I couldnt do anymore, Schultz says. Dropping out of school was one of the hardest things Ive ever done. As someone who loves learning, being unable to continue studying a subject I was incredibly passionate about was devastating. To admit I was sick enough to have to stop school alone was incredibly hard to do. Many people with disabilities struggle with coming to terms with limitations that we face, and this was that moment for me.

And over the next year, Schultzs depression grew deeper. A close friend had died. Their dream of having a career in world diplomacy was over. And their body just kept letting them down. But somehow, from somewhere deep inside, there was a little voice that told them not to give up.

One of the first things Schultz did was put their energy into their blog. It was an outlet for me to process what I was dealing withand help others by talking about it, they explain. Researching topics to write led me to writing for other organizations and to some really cool opportunities such as attending conferences using a press pass.

They also started volunteering, just a few hours a month at first, with the Arthritis Foundations Arthritis Ambassador Group as way to help enact change, and soon was invited to speak at events.

After that, my volunteering picked up, Schultz says. I was working with not only the AF but also with the International Autoimmune Arthritis Movement, National Arthritis Research Foundation, and other arthritis-based orgs. Doing all this helped me truly feel like I was giving back.

By 2014, Schultz felt like their life was starting to pick back up. They got married, continued with their advocacy work, and even started a new job at the local medical school, which opened their eyes to whole other side of health care, especially the quality-improvement process. Seeing what happens on the healthcare-system side and combining that with what I've seen from the patient side pushed me to want to help improve the overall system, they say.

Schultz had found a new path, perhaps the one they were always meant to follow. In 2015, they began a new masters degree in health administration with a focus on patient advocacy. But this time, they enrolled in an online program to better protect their health.

"Going to school online was such a better fit for me, Schultz says. I could work on classwork, group projects, and attend virtual classes without having to worry about germs, parking, or even wearing pants! Once I got back into the grove of attending classes, I felt amazing. The excitement that I have always felt about learning came back and, for the first time in three years, it felt like my brain fog had lifted."

Finally, in 2017, Schultz earned their degree. "To go from being unable to finish my previous attempt to finishing this one that meant so much more to me personally because of the subject matterits something that I can't describe in words very well. Just knowing I was smart enough and could accomplish this was well worth the degree."

But even with this huge accomplishment to launch them into their next chapter, Schultzs health pulled them back once again. On top of their RA symptoms, Schultz was diagnosed with two additional conditions, hypermobility syndrome, which had been causing increased joint pain, and mast-cell activation syndrome (MCAS), an immunological condition that can cause anaphylaxis and near-anaphylaxis.

The hypermobility was something that I have always had, but it was never diagnosed, Schultz explains. The MCAS makes them extremely sensitive to certain common chemicals. I cant walk down the detergent aisle in the supermarket because I cant take the fumes. Just breathing in certain products triggers symptoms of mild anaphylaxis for me.

For a while, Schultz opted to work part-time and continue advocating for other people via their websites. Along with their blog, they founded Chronic Sex.org, an online forum for people who have disabilities to discuss and learn about sexual issues. Schultz got the idea after attending an Arthritis Introspective conference at which they realized that a lot of the attendees, old and young alike, didnt really know much about basic sexual education. I realized how many people with disabilities get excluded from sex ed, and I wanted to start a forum to help change that, Schultz recalled.

Schultz has traveled internationally to speak at conferences, launched a podcast, and is in the process of developing a Chronic Sex research arm, called ORCHIDS: The Organization for Research on CHronic Illness, Disability, and Sexuality. Then last year, Schultz got their dream job working for a nonprofit dedicated to advocating for the rights of people with disabilities.

"I feel very honored to [help] create positive change. While working in health and sexuality are completely different than what I expected to be doing when I finished my undergraduate degree, I've been able to find ways to still do things I enjoy like research and giving talks, Schultz says. Being able to take on projects and get grants has been wonderfully emotionally. These were things I didn't think I'd be able to do in 2012, and I feel very lucky. My health is still an issue, but thankfully it gets to be on the backburner more days than notand that's pretty great."

Also pretty great? Schultzs journey with arthritis helped them discover another passion. Theyd been in physical therapy when theyd discovered a local LGBTQ hockey team. Throughout their work with Chronic Sex, Schultz had learned a lot about who they were, too, including that they were non-binary and pansexual. Their marriage had ended partly as a result.

"I had been so sick all the time and always had to figure out how to manage my health issues, Schultz explains. I never really had time to have a social life and, with the divorce, I needed to fix that. So Schultz ask their P.T. if itd be safe to play, and the therapist was 110% supportive, Schultz recalls.

The first day of hockey was comical, and I was very sore afterwards, Schultz says. I mean, here I am living with arthritis and my body doesnt move correctly anyway, and there I am standing on skates on the ice. But I loved it and, even though I only skated for five minutes of the entire hour, I couldnt wait to go back.

Schultz plays goalie, a position that taught its own set of lessons. They say: As goalie, I have learned that one night you can stop every puck and another night, you can stop none. There is a lot of luck involved. I think knowing this has made it a lot easier for me to let go and not feel like I have to be in control all the time.

The team has also been a source of new friendships. The amount of support that I have gotten has been incredible, Schultz says. Having a really large group of people to lean on for support has been completely life-changing.

Schultz always likes to have a plan in place, and theyre feeling good as they look forward to the years ahead: I am still going with the notion of not putting a lot of expectations on myself and on what my future looks like, they say. But I've started to work with my body more often than against it. Funny enough, part of teaching other people about self-love and self-esteem has meant having to learn what I teach! That alone has been worth this entire journey. Instead of getting upset at my body, I give myself space and graceto mess up, rest, and try again tomorrow."

See the rest here:
They're Back in the Game - HealthCentral.com

Read More...

Page 34«..1020..33343536..4050..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick